Bonel, Harald

Everts-Graber, Judith

Gahl, Brigitta

Häuselmann, HansJörg

Lehmann, Daniel

Lehmann, Thomas

Reichenbach, Stephan

Studer, Ueli

Ziswiler, Hans-Rudolf

English

Bern Open Repository and Information System (BORIS)

source: https://doi.org/10.48350/185548 | downloaded: 29.9.2023Vol.:(0123456789) Osteoporosis International https://doi.org/10.1007/s00198-023-06887-4CORRECTIONCorrection to: Comparison of anti‑fracture effectiveness of zoledronate, ibandronate and alendronate versus denosumab in a registry‑based cohort studyJudith Everts‑Graber1,2  · Harald Bonel3,4,5 · Daniel Lehmann6 · Brigitta Gahl7  · HansJörg Häuselmann8 · Ueli Studer1 · Hans‑Rudolf Ziswiler1 · Stephan Reichenbach2,9  · Thomas Lehmann1  © The Author(s) 2023Correction to:  Osteoporosis International https://doi.org/10.1007/s00198-023-06863-yIn this article the first reference in the Discussion section was incorrectly given as 19 but should have been 20. And all subsequent references (21 to 37) should have been one number higher.The legend for Fig.  1 (B) and (C) were inadvertently swapped; the figure legend should have been “ibandronate (B), alendronate (C)”The original article has been corrected.Open Access This article is licensed under a Creative Commons Attri-bution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Com-mons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regula-tion or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.Publisher's note Springer Nature remains neutral with regard to juris-dictional claims in published maps and institutional affiliations.The original article can be found online at https:// doi. org/ 10. 1007/ s00198- 023- 06863-y. * Judith Everts-Graber  judith.everts@hin.ch1 OsteoRheuma Bern AG, Bahnhofplatz 1, CH- 3011 Bern, Switzerland2 Department of Rheumatology and Immunology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland3 Campus Stiftung Lindenhof Bern, Swiss Institute for Translational and Entrepreneurial Medicine, Bern, Switzerland4 Department of Radiology, Lindenhof Hospital, Bern, Switzerland5 Department of Radiology, Inselspital, University of Bern, Bern, Switzerland6 Faculty of Medicine, University of Bern, Bern, Switzerland7 Clinical Trial Unit, University of Bern, Bern, Switzerland8 Zentrum Für Rheuma- Und Knochenerkrankungen, Klinik Im Park, Hirslanden Zurich, Switzerland9 Institute for Social and Preventive Medicine, University of Bern, Bern, Switzerland

Correction to: Comparison of anti-fracture effectiveness of zoledronate, ibandronate and alendronate versus denosumab in a registry-based cohort study.

https://boris.unibe.ch/185548/1/s00198-023-06887-4.pdf

Correction to: Comparison of anti-fracture effectiveness of zoledronate, ibandronate and alendronate versus denosumab in a registry-based cohort study.

Abstract

Similar works

Full text

Available Versions

Bern Open Repository and Information System (BORIS)